

# Birgit Burkhardt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2946381/publications.pdf>

Version: 2024-02-01

134  
papers

16,192  
citations

50276  
46  
h-index

17592  
121  
g-index

142  
all docs

142  
docs citations

142  
times ranked

26960  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epsteinâ€Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. British Journal of Haematology, 2022, 196, 681-689.	2.5	18
2	Design of a targeted nextâ€Cgeneration DNA sequencing panel for pediatric Tâ€Ccell lymphoblastic lymphoma to unravel biology and optimize treatment. Genes Chromosomes and Cancer, 2022, 61, 459-470.	2.8	2
3	Patient parameters and response after administration of rituximab in pediatric mature Bâ€Ccell nonâ€Hodgkin lymphoma. Pediatric Blood and Cancer, 2022, 69, e29514.	1.5	3
4	The genomic and transcriptional landscape of primary central nervous system lymphoma. Nature Communications, 2022, 13, 2558.	12.8	52
5	The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726.	2.7	1
6	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nature Communications, 2022, 13, .	12.8	28
7	Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group. Haematologica, 2021, 106, 1390-1400.	3.5	5
8	Second malignant neoplasms after treatment of non-Hodgkinâ€TM's lymphomaâ€a retrospective multinational study of 189 children and adolescents. Leukemia, 2021, 35, 534-549.	7.2	10
9	Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma. Leukemia, 2021, 35, 639-643.	7.2	16
10	Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. Blood, 2021, 137, 2347-2359.	1.4	31
11	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. Journal of Clinical Oncology, 2021, 39, 295-307.	1.6	163
12	Primary postâ€transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients. British Journal of Haematology, 2021, 193, 1178-1184.	2.5	11
13	Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. Cancers, 2021, 13, 2075.	3.7	23
14	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110
15	Molecular features of nonâ€Cnaplastic peripheral Tâ€Ccell lymphoma in children and adolescents. Pediatric Blood and Cancer, 2021, 68, e29285.	1.5	6
16	Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma. Haematologica, 2021, 106, 3232-3235.	3.5	8
17	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nature Medicine, 2021, 27, 1806-1817.	30.7	79
18	Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphomaâ€A Report from the ALL-REZ Study Group. Journal of Clinical Medicine, 2021, 10, 5292.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Cryptic insertion of <i>MYC</i> exons 2 and 3 into the immunoglobulin heavy chain locus detected by whole genome sequencing in a case of <i>MYC</i> -negative Burkitt lymphoma. <i>Haematologica</i> , 2020, 105, e202-e205.	3.5	24
20	Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial. <i>Leukemia</i> , 2020, 34, 613-624.	7.2	19
21	Treatment and outcome of IG-MYC+ neoplasms with precursor B-cell phenotype in childhood and adolescence. <i>Leukemia</i> , 2020, 34, 942-946.	7.2	5
22	Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic hematopoietic stem cell transplantation. <i>Mycoses</i> , 2020, 63, 172-180.	4.0	15
23	Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. <i>Cancers</i> , 2020, 12, 2747.	3.7	38
24	Sex differences in oncogenic mutational processes. <i>Nature Communications</i> , 2020, 11, 4330.	12.8	60
25	CopyDetective: Detection threshold-aware copy number variant calling in whole-exome sequencing data. <i>GigaScience</i> , 2020, 9, .	6.4	5
26	Rare non-Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28416.	1.5	32
27	Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia. <i>Blood Advances</i> , 2020, 4, 1760-1769.	5.2	27
28	Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 1996-2007.	2.4	18
29	Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28523.	1.5	8
30	Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. <i>Leukemia</i> , 2020, 34, 2271-2275.	7.2	9
31	Progressive or Relapsed Burkitt Lymphoma or Leukemia in Children and Adolescents after BFM-type First-line Therapy. <i>Blood</i> , 2020, 135, 1124-1132.	1.4	25
32	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group. <i>American Journal of Hematology</i> , 2020, 95, 809-816.	4.1	30
33	Experience with provisional WHO entities large B-cell lymphoma with <i>IRF4</i> rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group. <i>British Journal of Haematology</i> , 2020, 190, 753-763.	2.5	46
34	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. <i>Haematologica</i> , 2019, 104, e17-e20.	3.5	18
35	Epidemiology and management burden of invasive fungal infections after autologous hematopoietic stem cell transplantation: 10-year experience at a European Pediatric Cancer Center. <i>Mycoses</i> , 2019, 62, 954-960.	4.0	9
36	Lymphoblastic Lymphoma. , 2019, , 153-164.		0

#	ARTICLE	IF	CITATIONS
37	Marginal Zone Lymphoma. , 2019, , 221-227.		0
38	MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma. Cancer Research, 2019, 79, 3125-3138.	0.9	19
39	Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. British Journal of Haematology, 2019, 185, 1158-1170.	2.5	60
40	Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nature Communications, 2019, 10, 1459.	12.8	99
41	ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. European Journal of Cancer, 2019, 110, 74-85.	2.8	39
42	Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents. Blood Advances, 2019, 3, 4291-4297.	5.2	17
43	Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma. Genes Chromosomes and Cancer, 2019, 58, 365-372.	2.8	6
44	Solid organ transplantation after hematopoietic stem cell transplantation in childhood: A multicentric retrospective survey. American Journal of Transplantation, 2019, 19, 1798-1805.	4.7	9
45	The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood, 2019, 133, 962-966.	1.4	69
46	CD38 is not expressed in pediatric ALK-positive anaplastic large cell lymphoma. Pediatric Blood and Cancer, 2019, 66, e27541.	1.5	1
47	Durable control of hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic haematopoietic stem cell transplantation. Journal of Viral Hepatitis, 2019, 26, 454-458.	2.0	3
48	Aggressive Lymphoma in Children and Adolescents. Mechanical Engineering Series, 2019, , 245-282.	0.2	0
49	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
50	Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection. Pediatric Blood and Cancer, 2018, 65, e26932.	1.5	18
51	Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. Leukemia and Lymphoma, 2018, 59, 1213-1221.	1.3	18
52	Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma. British Journal of Haematology, 2018, 182, 735-739.	2.5	12
53	IG-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. Blood, 2018, 132, 2280-2285.	1.4	50
54	Malignant Lymphomas in Childhood. , 2018, , 1330-1342.e5.		2

#	ARTICLE	IF	CITATIONS
55	Stem Cell Transplantation for Pediatric Patients with Non-Anaplastic Peripheral T-Cell Lymphoma on Behalf of the EBMT-Pediatric Diseases Working Party. <i>Blood</i> , 2018, 132, 5787-5787.	1.4	0
56	Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies. <i>Blood</i> , 2018, 132, 3354-3354.	1.4	0
57	Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols. <i>Haematologica</i> , 2017, 102, 1091-1098.	3.5	47
58	Childhood cancer predisposition syndromes – A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	1.2	200
59	Control of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in Allogeneic Hematopoietic Stem Cell Transplant Recipients by a Novel Bundle Including Remodeling of Sanitary and Water Supply Systems. <i>Clinical Infectious Diseases</i> , 2017, 65, 935-942.	5.8	34
60	Mature aggressive B-cell lymphoma across age groups – molecular advances and therapeutic implications. <i>Expert Review of Hematology</i> , 2017, 10, 123-135.	2.2	4
61	Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy. <i>British Journal of Haematology</i> , 2017, 179, 272-283.	2.5	25
62	Cell-of-origin classification by gene expression and <i>MYC</i> rearrangements in diffuse large B-cell lymphoma of children and adolescents. <i>British Journal of Haematology</i> , 2017, 179, 116-119.	2.5	23
63	Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. <i>Haematologica</i> , 2017, 102, 2086-2096.	3.5	56
64	Immunohistochemical detection of inhibitor of DNA binding 3 mutational variants in mature aggressive B-cell lymphoma. <i>Haematologica</i> , 2016, 101, e259-e261.	3.5	2
65	Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. <i>British Journal of Haematology</i> , 2016, 173, 545-559.	2.5	44
66	Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. <i>Haematologica</i> , 2016, 101, 1581-1591.	3.5	58
67	Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis. <i>Haematologica</i> , 2016, 101, 1380-1389.	3.5	43
68	The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2016, 127, 3281-3290.	1.4	83
69	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	2.8	262
70	Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. <i>Annals of Hematology</i> , 2016, 95, 1503-1512.	1.8	16
71	Clinical Heterogeneity in RUNX1-Associated Familial Myelodysplastic Syndrome - Report of Two Novel Pedigrees with Childhoodleukemia. <i>Blood</i> , 2016, 128, 5509-5509.	1.4	1
72	XI. Management of paediatric and adult non-Hodgkin lymphoma: what lessons can each teach the other?. <i>Hematological Oncology</i> , 2015, 33, 62-66.	1.7	1

#	ARTICLE	IF	CITATIONS
73	Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations. British Journal of Haematology, 2015, 170, 814-825.	2.5	36
74	Clinical and pathological features of Burkitt lymphoma showing expression of $BCL2$ – an analysis including gene expression in formalin-fixed paraffin-embedded tissue. British Journal of Haematology, 2015, 171, 501-508.	2.5	23
75	The <i>PCBP1</i> gene encoding poly(rc) binding protein i is recurrently mutated in $B$ urkitt lymphoma. Genes Chromosomes and Cancer, 2015, 54, 555-564.	2.8	29
76	Childhood acute lymphoblastic leukemia-associated risk-loci KZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-Münster Study Group. Leukemia and Lymphoma, 2015, 56, 814-816.	1.3	9
77	Multiplex ligation-dependent probe amplification validates LOH6q analyses and enhances insight into chromosome 6q aberrations in pediatric T-cell lymphoblastic leukemia and lymphoma. Leukemia and Lymphoma, 2015, 56, 1884-1887.	1.3	4
78	Immunoreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?. Cancers, 2015, 7, 305-328.	3.7	45
79	Non-neoplastic peripheral T-cell lymphoma in children and adolescents – a retrospective analysis of the $NHL-BFM$ study group. British Journal of Haematology, 2015, 168, 835-844.	2.5	42
80	DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control. Nature Genetics, 2015, 47, 1316-1325.	21.4	119
81	Whole exome sequencing hints at a unique mutational profile of paediatric T-cell lymphoblastic lymphoma. British Journal of Haematology, 2015, 168, 308-313.	2.5	30
82	Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. Journal of Clinical Oncology, 2015, 33, 2963-2974.	1.6	202
83	MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5261-70.	7.1	91
84	Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma. European Journal of Haematology, 2014, 93, 349-353.	2.2	5
85	Recurrent <i>RHOA</i> mutations in pediatric $B$ urkitt lymphoma treated according to the NHL-BFM protocols. Genes Chromosomes and Cancer, 2014, 53, 911-916.	2.8	51
86	Primary central nervous system lymphoma in children and adolescents: low relapse rate after treatment according to Non-Hodgkin-Lymphoma Berlin-Frankfurt-Munster protocols for systemic lymphoma. Haematologica, 2014, 99, e238-e241.	3.5	29
87	A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood, 2014, 123, 1187-1198.	1.4	185
88	Relapsed or Refractory Burkitt Lymphoma in Children and Adolescents after BFM-Type First-Line Therapy - a BFM Group Report. Blood, 2014, 124, 1738-1738.	1.4	2
89	Proposal of a Genetic Classifier for Risk Group Stratification in Pediatric T-Cell Lymphoblastic Lymphoma Reveals Significant Differences to T-Cell Lymphoblastic Leukemia. Blood, 2014, 124, 2398-2398.	1.4	1
90	Abstract 3092: PTEN mutations correlate with relapse risk in pediatric T-cell lymphoblastic lymphoma patients: Validation of whole exome sequencing results. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
91	New Insights into Potential Driver Mutations in Pediatric Burkitt Lymphoma. <i>Blood</i> , 2014, 124, 2980-2980.	1.4	0
92	Treatment of Adolescents with Aggressive B-Cell Malignancies: The Pediatric Experience. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 226-235.	2.3	7
93	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	27.8	8,060
94	Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "watch and wait" strategy after complete resection. <i>Annals of Hematology</i> , 2013, 92, 1537-1541.	1.8	65
95	Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. <i>Blood</i> , 2013, 121, 3153-3160.	1.4	105
96	High resolution copy number analysis of <i>IRF4</i> translocation-positive diffuse large B-cell and follicular lymphomas. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 150-155.	2.8	30
97	Mature B-Cell Lymphoma and Leukemia in Children and Adolescents"Review of Standard Chemotherapy Regimen and Perspectives. <i>Pediatric Hematology and Oncology</i> , 2013, 30, 465-483.	0.8	26
98	Lymphoblastic Lymphoma in Childhood and Adolescence. <i>Pediatric Hematology and Oncology</i> , 2013, 30, 484-508.	0.8	31
99	Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in <i>IRF4</i> translocation negative pediatric follicular lymphomas. <i>Haematologica</i> , 2013, 98, 1237-1241.	3.5	65
100	Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 119, 1882-1887.	1.4	163
101	Cell cycle regulatory molecular profiles of pediatric T-cell lymphoblastic leukemia and lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 557-568.	1.3	9
102	Recurrent mutation of the <i>ID3</i> gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. <i>Nature Genetics</i> , 2012, 44, 1316-1320.	21.4	389
103	The <i>CBFA2T3/ACSF3</i> locus is recurrently involved in <i>IGH</i> chromosomal translocation <i>t</i> (14;16)(q32;q24) in pediatric B-cell lymphoma with germinal center phenotype. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 338-343.	2.8	18
104	Prognostic Impact of Fc Gamma-Receptor Polymorphisms and Efficacy of Rituximab in Children and Adolescents with Mature Aggressive B-NHL. <i>Blood</i> , 2012, 120, 1547-1547.	1.4	0
105	Diagnosis and Immunophenotype of 188 Pediatric Lymphoblastic Lymphomas Treated Within a Randomized Prospective Trial. <i>American Journal of Surgical Pathology</i> , 2011, 35, 836-844.	3.7	54
106	Translocations activating <i>IRF4</i> identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. <i>Blood</i> , 2011, 118, 139-147.	1.4	281
107	Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen breakage syndrome): a retrospective survey. <i>British Journal of Haematology</i> , 2011, 155, 468-476.	2.5	51
108	Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. <i>Haematologica</i> , 2011, 96, 262-268.	3.5	92



#	ARTICLE	IF	CITATIONS
109	Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)â€‘Type First-Line Therapy: A BFM-Group Study. Journal of Clinical Oncology, 2011, 29, 3065-3071.	1.6	101
110	Paediatric lymphoblastic Tâ€‘cell leukaemia and lymphoma: one or two diseases?. British Journal of Haematology, 2010, 149, 653-668.	2.5	68
111	Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. Haematologica, 2010, 95, 158-162.	3.5	32
112	Pediatric follicular lymphoma - a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma - Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica, 2010, 95, 253-259.	3.5	107
113	Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica, 2010, 95, 2047-2055.	3.5	70
114	Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinaseâ€‘positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood, 2010, 115, 3314-3319.	1.4	111
115	Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia. Journal of Clinical Oncology, 2010, 28, 3115-3121.	1.6	170
116	Novel oncogene amplifications in tumors from a family with Liâ€‘Fraumeni syndrome. Genes Chromosomes and Cancer, 2009, 48, 558-568.	2.8	13
117	Poor Outcome for Children and Adolescents With Progressive Disease or Relapse of Lymphoblastic Lymphoma: A Report From the Berlin-Frankfurt-Muenster Group. Journal of Clinical Oncology, 2009, 27, 3363-3369.	1.6	147
118	Genomic profiling reveals different genetic aberrations in systemic ALKâ€‘positive and ALKâ€‘negative anaplastic large cell lymphomas. British Journal of Haematology, 2008, 140, 516-526.	2.5	145
119	Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leukemia and Lymphoma, 2008, 49, 451-461.	1.3	56
120	Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood, 2008, 112, 1374-1381.	1.4	112
121	Circulating Antibodies to ALK Inversely Correlat with Relapse Risk and Circulating Tumor Cells in Children and Adolescents with ALK-Positive Anaplastic Large Cell Lymphoma. Blood, 2008, 112, 2831-2831.	1.4	0
122	Poor Outcome for Children and Adolescents with Progressive Disease or Relapse of Lymphoblastic Lymphoma - a Report of the BFM Group. Blood, 2008, 112, 3589-3589.	1.4	0
123	Prevalence, Clinical Pattern, and Outcome of CNS Involvement in Childhood and Adolescent Non-Hodgkin's Lymphoma Differ by Non-Hodgkin's Lymphoma Subtype: A Berlin-Frankfurt-MÃ¼nster Group Report. Journal of Clinical Oncology, 2007, 25, 3915-3922.	1.6	99
124	Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALKâ€‘positive anaplastic large-cell lymphoma. Blood, 2007, 110, 670-677.	1.4	130
125	Clinical characteristics and treatment outcome of infants with non-Hodgkin lymphoma. British Journal of Haematology, 2007, 139, 070916051811006-???.	2.5	26
126	Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Mul'nster) Multicenter Trial. Blood, 2006, 107, 4047-4052.	1.4	163



#	ARTICLE	IF	CITATIONS
127	Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents - a Berlin-Frankfurt-Munster group report. British Journal of Haematology, 2006, 133, 176-182.	2.5	119
128	Impact of Cranial Radiotherapy on Central Nervous System Prophylaxis in Children and Adolescents With Central Nervous Systemâ€“Negative Stage III or IV Lymphoblastic Lymphoma. Journal of Clinical Oncology, 2006, 24, 491-499.	1.6	146
129	Pediatric T-Cell Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma: Differences in the Common Deleted Region and the Prognostic Impact of Chromosome 6q Deletions.. Blood, 2006, 108, 294-294.	1.4	1
130	The impact of age and gender on biology, clinical features and treatment outcome of nonâ€“Hodgkin lymphoma in childhood and adolescence. British Journal of Haematology, 2005, 131, 39-49.	2.5	278
131	Tumor Necrosis Factor and Lymphotoxin Alfa Genetic Polymorphisms and Outcome in Pediatric Patients With Non-Hodgkinâ€™s Lymphoma: Results From Berlin-Frankfurt-MÃ¼nster Trial NHL-BFM 95. Journal of Clinical Oncology, 2005, 23, 8414-8421.	1.6	50
132	Secondary Neoplasms Subsequent to Berlin-Frankfurt-Muenster (BFM) Therapy of Non-Hodgkin Lymphoma of Childhood: Significantly Higher Risk for Patients with Lymphoblastic Lymphoma Compared to Other NHL-Subtypes.. Blood, 2005, 106, 232-232.	1.4	8
133	The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood, 2004, 105, 948-958.	1.4	304
134	Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia. Leukemia, 0, , .	7.2	1